Unlocking the Genetic Secrets of Pediatric Brain and Spinal Cord Tumors
A groundbreaking study reveals how rare genetic variants inherited from parents impact the development and outcomes of brain and spinal cord cancers in children. But here's the twist: many of these genetic risks are going unnoticed, leaving a crucial piece of the puzzle unsolved in the fight against childhood cancer.
Researchers from leading children's hospitals have delved into the role of inherited genetic variants in pediatric brain and spinal cord tumors. Their findings, published in Nature Communications, shed light on the complex interplay between genetics and cancer.
Cancers of the central nervous system (CNS) are a leading cause of cancer-related deaths in children, affecting over 47,000 young lives annually. Surprisingly, up to 25% of children with cancer carry rare genetic variants that elevate their risk, yet the genetic triggers of pediatric CNS tumors remain a mystery.
The study focused on pathogenic (P) and likely pathogenic (LP) germline variants, which are known or suspected to increase disease risk, respectively. By analyzing blood and tumor samples from 830 children in the Pediatric Brain Tumor Atlas, researchers aimed to uncover the genetic changes that make some children more susceptible to these cancers.
And here's where it gets intriguing: nearly 25% of the children had a genetic change in a cancer-risk-associated gene, with 7% already diagnosed with a related genetic condition. Even more striking, 6% had genetic changes in CNS tumor-related genes that had not been clinically identified before. This suggests that many inherited genetic risks are currently slipping through the cracks, emphasizing the need for comprehensive genetic testing in pediatric cancer care.
The study also revealed a fascinating pattern: 35% of children with these genetic variants had additional changes in the same genes within their tumors, resulting in impaired gene function. This supports the 'two-hit' theory of cancer development, where one genetic alteration is inherited and a second occurs in the tumor.
But what does this mean for the future of pediatric cancer treatment?
"By understanding these genetic risk factors and patterns, we can develop more personalized and effective therapies for children with CNS tumors," explains Dr. Sharon J. Diskin, the study's senior author.
The research team is now expanding their study to include parental sequencing and more patients, aiming to unravel the complex interactions between inherited and tumor-specific genetic changes. This could revolutionize how we diagnose and treat pediatric brain and spinal cord cancers, offering new hope for improved outcomes.
This study was funded by various institutions, including the National Institutes of Health and the Children's Brain Tumor Network, highlighting the collaborative efforts in the quest to conquer childhood cancer.
